IL-21 is a broad negative regulator of IgE class switch recombination in mouse and human B cells

IgE antibodies may elicit potent allergic reactions, and their production is tightly controlled. The tendency to generate IgE has been thought to reflect the balance between type 1 and type 2 cytokines, with the latter promoting IgE. Here, we reevaluated this paradigm by a direct cellular analysis,...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of experimental medicine Vol. 217; no. 5
Main Authors Yang, Zhiyong, Wu, Chung-An M., Targ, Sasha, Allen, Christopher D.C.
Format Journal Article
LanguageEnglish
Published United States Rockefeller University Press 04.05.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:IgE antibodies may elicit potent allergic reactions, and their production is tightly controlled. The tendency to generate IgE has been thought to reflect the balance between type 1 and type 2 cytokines, with the latter promoting IgE. Here, we reevaluated this paradigm by a direct cellular analysis, demonstrating that IgE production was not limited to type 2 immune responses yet was generally constrained in vivo. IL-21 was a critical negative regulator of IgE responses, whereas IFN-γ, IL-6, and IL-10 were dispensable. Follicular helper T cells were the primary source of IL-21 that inhibited IgE responses by directly engaging the IL-21 receptor on B cells and triggering STAT3-dependent signaling. We reconciled previous discordant results between mouse and human B cells and revealed that the inhibition of IgE class switch recombination by IL-21 was attenuated by CD40 signaling, whereas IgG1 class switch recombination was potentiated by IL-21 in the context of limited IL-4. These findings establish key features of the extrinsic regulation of IgE production by cytokines.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Disclosures: The authors declare no competing interests exist.
ISSN:0022-1007
1540-9538
1540-9538
DOI:10.1084/jem.20190472